All articles by
Emergex unveils positive data from Phase 1 trial of CoronaTcP
According to the trial’s primary outcome measures, CoronaTcP showed a satisfactory safety profile, with no serious adverse events associated with the treatment
SURGE Therapeutics secures $32m to advance intraoperative immunotherapy
The Series B funding round was led by Bioluminescence Ventures, with participation from KdT Ventures, Piedmont Capital, and others
Tenax secures US patent for oral levosimendan in PH-HFpEF treatment
The oral levosimendan treatment for PH-HFpEF is covered by the issued patent (US Patent No. 11,701,355), which grants exclusivity until December 2040
Co-Diagnostics, Inc. Announces Recent Grant Awards
The Company intends to use funds awarded by the Bill & Melinda Gates Foundation toward completion of tuberculosis and HPV tests for its Co-Dx PCR Home™ platform
Detection of Enterovirus E-11 by qPCR
On 5 May 2023, France reported an increase in cases of severe neonatal sepsis associated with Enterovirus
(Echovirus-11 (E-11)).
J&J to pay $18.8m to California cancer patient in baby powder trial
Emory Hernandez Valadez claims that heavy exposure to the company’s talc starting in his early years led to the development of mesothelioma in the tissue surrounding his heart
Harrow buys US and Canadian rights to certain ophthalmic products of Santen
The products involved in the deal include FLAREX, NATACYN, TOBRADEX ST, VERKAZIA, ZERVIATE, and non-prescription brands FRESHKOTE and Cationorm PLUS
Neumora Therapeutics Announces Initiation of Phase 3 Clinical Program for Navacaprant in Major Depressive Disorder
In a Phase 2 study, navacaprant (NMRA-140) monotherapy demonstrated statistically significant and clinically meaningful reductions in symptoms of depression and anhedonia in participants with moderate-to-severe MDD
QIAGEN expands range of digital PCR kits and services for the biopharma industry
New partnership with Niba Labs to offer customized digital PCR (dPCR) assay design services to biopharma customers. Launch of CGT Viral Vector Lysis Kit enabling standardized workflow from cell lysates to absolute and precise quantification of viral titers. Biopharmaceutical companies increasingly adopting dPCR technology for enhanced drug safety and efficacy in drug development process
BridgeBio’s acoramidis shows positive results in Phase 3 study
In the trial, acoramidis showed statistically significant improvement in the primary endpoint by a Win Ratio of 1.8 and meaningful treatment benefits at 30 months on the secondary endpoints